Form 4: Macrogenics Director Federica F. O'Brien Reports Stock Transactions
SEC Form 4 Filing
Director Federica F. O'Brien reports acquisition of common stock, restricted stock units, and stock options in Macrogenics Inc.
Summary
- On May 20, 2025, Federica F. O'Brien, a director of Macrogenics Inc., acquired 6,500 shares of common stock.
- O'Brien also acquired 6,500 Restricted Stock Units (RSUs) that vested on May 20, 2025.
- On May 21, 2025, O'Brien acquired 3,750 RSUs that will vest one year from the grant date or the day prior to the next annual meeting, if earlier.
- Additionally, O'Brien acquired stock options to buy 22,000 shares at $1.49, vesting in monthly increments over one year.
- O'Brien also acquired stock options to buy 64,961 shares at $1.27, vesting in monthly increments over one year, in lieu of direct cash compensation.
- Following these transactions, O'Brien directly owns 11,000 shares of common stock, 3,750 RSUs, 22,000 stock options at $1.49, and 86,961 stock options at $1.27.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects insider transactions, which could be interpreted as positive or negative depending on the investor's perspective, but the filing itself is simply a factual report.
Positives
- The director's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Comparison to Industry Standards
- Director compensation packages often include stock options and RSUs to align their interests with shareholders, a common practice among publicly traded biotechnology companies.
- The vesting schedules and exercise prices of the options appear typical for such grants.
Stakeholder Impact
- Shareholders can use this information to assess the director's alignment with their interests.
- The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of common stock acquisition and RSU vesting. |
| 05/21/2025 | Date of RSU and stock option acquisitions; date of the Issuer's 2025 Annual Meeting of Stockholders. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
| 05/21/2035 | Expiration date of stock options. |
Keywords
Macrogenics, MGNX, Director, Stock Options, Restricted Stock Units, Common Stock, Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.